Appili Therapeutics Stock Today
| APLI Stock | CAD 0.04 0.01 16.67% |
PerformanceInsignificant
| Odds Of DistressVery High
|
Appili Therapeutics is selling at 0.035 as of the 21st of March 2025; that is 16.67 percent increase since the beginning of the trading day. The stock's open price was 0.03. Appili Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 21st of December 2024 and ending today, the 21st of March 2025. Click here to learn more.
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada. The company has 121.27 M outstanding shares of which 1.87 K shares are presently shorted by private and institutional investors with about 0.03 days to cover all short positions. More on Appili Therapeutics
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Appili Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Appili Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Appili Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
Appili Therapeutics (APLI) is traded on Toronto Exchange in Canada and employs 6 people. Appili Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 4.24 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Appili Therapeutics's market, we take the total number of its shares issued and multiply it by Appili Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Appili Therapeutics operates under Biotechnology sector and is part of Health Care industry. The entity has 121.27 M outstanding shares of which 1.87 K shares are presently shorted by private and institutional investors with about 0.03 days to cover all short positions.
Appili Therapeutics has accumulated about 5.55 M in cash with (2.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.05, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Appili Therapeutics Probability Of Bankruptcy
Ownership AllocationAppili Therapeutics holds a total of 121.27 Million outstanding shares. Almost 88.1 percent of Appili Therapeutics outstanding shares are held by general public with 0.06 (percent) owned by insiders and only 11.84 % by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Appili Ownership Details
Appili Therapeutics Risk Profiles
Although Appili Therapeutics' alpha and beta are two of the key measurements used to evaluate Appili Therapeutics' performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 5.79 | |||
| Semi Deviation | 6.91 | |||
| Standard Deviation | 9.93 | |||
| Variance | 98.58 |
Appili Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Appili Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Aroon Oscillator Now
Aroon OscillatorAnalyze current equity momentum using Aroon Oscillator and other momentum ratios |
| All Next | Launch Module |
Appili Therapeutics Corporate Management
Elected by the shareholders, the Appili Therapeutics' board of directors comprises two types of representatives: Appili Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Appili. The board's role is to monitor Appili Therapeutics' management team and ensure that shareholders' interests are well served. Appili Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Appili Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Cilla MBA | Pres CEO | Profile | |
| MS MD | Chief Officer | Profile | |
| Kenneth Howling | Acting Officer | Profile | |
| Gary Nabors | Chief Officer | Profile |
Other Information on Investing in Appili Stock
Appili Therapeutics financial ratios help investors to determine whether Appili Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Appili with respect to the benefits of owning Appili Therapeutics security.